ArriVent BioPharma (AVBP) Stock Chart & Stock Price History → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free AVBP Stock Alerts $20.10 -0.05 (-0.25%) (As of 05/17/2024 ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media ArriVent BioPharma Stock Price Performance5 Day Performance+8.88%1 Month Performance+29.68%3 Month Performance-10.55% Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter Email Address Ad InvestorPlaceHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs AVBP Stock Chart for Sunday, May, 19, 2024 AVBP Chart by TradingView ArriVent BioPharma Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/17/2024$20.15$20.10-0.25%$20.85$19.9965,380 shs$673.15 million05/16/2024$19.50$20.15+3.33%$20.74$19.3056,995 shs$674.82 million05/15/2024$18.46$19.50+5.63%$19.55$18.7451,360 shs$653.06 million05/14/2024$17.93$18.46+2.96%$18.80$17.6839,373 shs$618.23 million05/13/2024$17.70$17.93+1.30%$18.51$16.9747,943 shs$600.48 million05/10/2024$17.99$17.70-1.61%$18.00$17.3927,905 shs$592.84 million Get the Latest News and Ratings for AVBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. 05/09/2024$17.36$17.99+3.63%$17.99$17.3630,615 shs$602.56 million05/08/2024$17.25$17.36+0.64%$17.85$16.8240,811 shs$581.46 million05/07/2024$17.24$17.25+0.06%$17.62$17.0241,505 shs$577.77 million05/06/2024$17.23$17.24+0.06%$17.63$16.9325,226 shs$577.37 million05/03/2024$16.80$17.23+2.56%$17.51$16.7623,943 shs$577.03 million05/02/2024$16.69$16.80+0.66%$17.39$16.5462,370 shs$562.70 million05/01/2024$16.52$16.69+1.03%$17.42$15.7965,808 shs$558.95 million04/30/2024$16.34$16.52+1.10%$16.96$15.66108,462 shs$553.26 million04/29/2024$15.44$16.34+5.83%$16.64$15.3652,617 shs$547.23 million04/26/2024$15.54$15.44-0.64%$16.47$15.4053,529 shs$517.09 million04/25/2024$15.30$15.54+1.57%$15.88$14.3568,890 shs$520.44 million04/24/2024$15.77$15.30-2.98%$16.08$14.75130,345 shs$512.40 million04/23/2024$15.90$15.77-0.82%$16.29$15.3186,950 shs$528.20 million04/22/2024$15.50$15.90+2.58%$16.65$15.60115,535 shs$532.49 million04/19/2024$15.50$15.50$16.26$15.1734,155 shs$519.10 million04/18/2024$16.04$15.50-3.37%$17.04$14.74629,988 shs$519.10 million04/17/2024$16.80$16.04-4.52%$16.93$15.50194,788 shs$537.18 million04/16/2024$17.00$16.80-1.18%$17.55$16.44258,462 shs$562.63 million04/15/2024$16.89$17.00+0.65%$17.35$16.55311,965 shs$569.33 million04/12/2024$17.67$16.89-4.41%$17.85$16.6797,650 shs$565.65 million04/11/2024$17.29$17.67+2.20%$17.95$17.1071,831 shs$591.77 million04/10/2024$17.33$17.29-0.23%$17.66$16.9196,319 shs$579.04 million04/09/2024$17.49$17.33-0.91%$17.83$17.15132,269 shs$580.45 million04/08/2024$18.45$17.49-5.20%$18.54$17.34137,708 shs$585.74 million04/05/2024$18.30$18.45+0.82%$18.98$18.1241,494 shs$617.89 million04/04/2024$18.12$18.30+0.99%$18.54$17.8577,510 shs$612.94 million04/03/2024$18.00$18.12+0.67%$18.20$17.87122,190 shs$606.84 million04/02/2024$18.31$18.00-1.69%$18.20$17.92138,099 shs$575.28 million04/01/2024$17.86$18.31+2.52%$19.11$17.74357,779 shs$585.19 million03/29/2024$17.86$17.86$18.30$17.73233,160 shs$570.75 million03/28/2024$18.00$17.86-0.78%$18.30$17.73233,160 shs$570.81 million03/27/2024$17.80$18.00+1.12%$18.31$17.50121,847 shs$575.28 million03/26/2024$16.96$17.80+4.95%$18.04$16.91132,790 shs$568.89 million03/25/2024$18.28$16.96-7.22%$18.22$16.90121,475 shs$542.04 millionHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.Click for his six specific AI stock in the crosshairs03/22/2024$18.21$18.28+0.38%$18.46$17.8484,716 shs$584.23 million03/21/2024$18.42$18.21-1.14%$18.51$17.58172,738 shs$581.99 million03/20/2024$18.13$18.42+1.60%$18.67$17.67178,129 shs$588.70 million03/19/2024$18.55$18.13-2.26%$18.57$17.65298,818 shs$579.38 million03/18/2024$19.49$18.55-4.82%$19.78$18.14301,289 shs$592.86 million03/15/2024$18.57$19.49+4.95%$20.15$18.281.97 million shs$622.90 million03/14/2024$19.75$18.57-5.97%$19.75$17.69261,998 shs$593.50 million03/13/2024$19.15$19.75+3.13%$19.83$19.02149,831 shs$631.21 million03/12/2024$19.33$19.15-0.93%$19.96$18.75159,785 shs$612.03 million03/11/2024$19.61$19.33-1.43%$20.32$19.10111,746 shs$617.79 million03/08/2024$20.10$19.61-2.44%$20.70$19.6191,477 shs$626.74 million03/07/2024$20.25$20.10-0.74%$20.72$19.65121,599 shs$642.40 million03/06/2024$20.43$20.25-0.88%$21.43$20.11107,710 shs$647.19 million03/05/2024$22.75$20.43-10.20%$22.50$20.43139,563 shs$652.88 million03/04/2024$20.94$22.75+8.64%$22.99$20.57183,082 shs$727.09 million03/01/2024$21.54$20.94-2.79%$22.20$20.60136,934 shs$669.24 million02/29/2024$20.45$21.54+5.33%$22.29$20.34169,140 shs$688.42 million02/28/2024$19.54$20.45+4.66%$21.01$19.12306,712 shs$653.58 million02/27/2024$18.94$19.54+3.17%$20.10$18.61229,685 shs$624.50 million02/26/2024$19.32$18.94-1.97%$19.67$18.63186,345 shs$605.32 million02/23/2024$19.67$19.32-1.78%$20.50$19.18183,099 shs$617.47 million02/22/2024$19.88$19.67-1.06%$20.14$18.37319,678 shs$628.65 million02/21/2024$20.63$19.88-3.64%$21.44$19.66219,872 shs$635.37 million02/20/2024$22.47$20.63-8.19%$22.75$20.31181,203 shs$659.27 million02/19/2024$22.47$22.47$22.51$21.2573,300 shs$718.14 million Related Companies: Lyell Immunopharma Stock Chart Zymeworks Stock Chart Silence Therapeutics Stock Chart GH Research Stock Chart Pharvaris Stock Chart Calliditas Therapeutics AB (publ) Stock Chart AnaptysBio Stock Chart Mineralys Therapeutics Stock Chart Savara Stock Chart Pharming Group Stock Chart Receive AVBP Stock News and Ratings via EmailSign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AVBP) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.